QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Akari Therapeutics Stock Price, News & Analysis (NASDAQ:AKTX)

$2.92
+0.01 (+0.34%)
(As of 11/28/2023 ET)
Compare
Today's Range
$2.85
$2.92
50-Day Range
$2.91
$4.13
52-Week Range
$2.81
$12.00
Volume
7,028 shs
Average Volume
20,766 shs
Market Capitalization
$16.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.00

Akari Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
927.4% Upside
$30.00 Price Target
Short Interest
Healthy
0.22% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.58mentions of Akari Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.13 out of 5 stars

Medical Sector

440th out of 949 stocks

Pharmaceutical Preparations Industry

199th out of 434 stocks


AKTX stock logo

About Akari Therapeutics Stock (NASDAQ:AKTX)

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

AKTX Stock Price History

AKTX Stock News Headlines

Akari Therapeutics, Plc (CLA.F)
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Akari Therapeutics to Present at Emerging Growth Conference
British pharma opens U.S. headquarters in Boston
Akari Therapeutics, Plc Announces ADS Ratio Change
See More Headlines
Receive AKTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akari Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/31/2020
Today
11/28/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AKTX
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.00
High Stock Price Target
$30.00
Low Stock Price Target
$30.00
Potential Upside/Downside
+934.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
2,159,000
Market Cap
$16.39 million
Optionable
Not Optionable
Beta
1.22
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Ms. Rachelle Suzanne Jacques (Age 52)
    President, CEO & Director
    Comp: $1.38M
  • Ms. Wendy F. DiCicco CPA (Age 56)
    Interim Chief Financial Officer
  • Ms. Melissa Bradford-Klug (Age 53)
    Chief Operating Officer
  • Dr. Miles Nunn (Age 54)
    Chief Scientific Officer
  • Dr. John F. Neylan III (Age 70)
    M.D., Executive VP & Chief Medical Officer
  • Ms. Beth-Anne Lang
    Senior Vice President of Regulatory Affairs
  • Annie Mack
    Financial Controller














AKTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Akari Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" AKTX shares.
View AKTX analyst ratings
or view top-rated stocks.

What is Akari Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Akari Therapeutics' stock. Their AKTX share price targets range from $30.00 to $30.00. On average, they anticipate the company's stock price to reach $30.00 in the next year. This suggests a possible upside of 927.4% from the stock's current price.
View analysts price targets for AKTX
or view top-rated stocks among Wall Street analysts.

How have AKTX shares performed in 2023?

Akari Therapeutics' stock was trading at $9.3980 on January 1st, 2023. Since then, AKTX stock has decreased by 68.9% and is now trading at $2.92.
View the best growth stocks for 2023 here
.

Are investors shorting Akari Therapeutics?

Akari Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 11,200 shares, a drop of 36.0% from the October 31st total of 17,500 shares. Based on an average trading volume of 15,200 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.2% of the shares of the company are short sold.
View Akari Therapeutics' Short Interest
.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics, Plc (NASDAQ:AKTX) posted its quarterly earnings data on Tuesday, March, 31st. The biopharmaceutical company reported ($7.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.80) by $5.00.

When did Akari Therapeutics' stock split?

Akari Therapeutics shares reverse split before market open on Thursday, August 17th 2023. The 1-20 reverse split was announced on Thursday, August 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Akari Therapeutics own?
Who are Akari Therapeutics' major shareholders?

Akari Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sabby Management LLC (3.15%).
View institutional ownership trends
.

How do I buy shares of Akari Therapeutics?

Shares of AKTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:AKTX) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -